Top Markets
#1 Black Phoenix Black Phoenix +3,787.95%
#2 Nesa Nesa +758.35%
#3 Ontology Gas Ontology Gas +154.35%
#4 ADO Protocol ADO Protocol +104.16%
#5 Cortex Cortex +95.89%
#6 Kinesis Silver Kinesis Silver +54.16%
#7 Non-Playable Coin Non-Playable Coin +34.27%
#8 Pons Pons +32.57%
#9 Ontology Ontology +31.01%
#10 Cash Cat Cash Cat +30.78%
Coin of the day
Black Phoenix Black Phoenix
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
UniQure N.V. UniQure N.V.

UniQure N.V.

QURE
Kedudukan dalam Saham #4587
uniQure N.V. develops treatments for patients suffering from rare and other... uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Harga Saham
$50.67
Modal Pasaran
$3.51B
Perubahan (1 hari)
-0.75%
Perubahan (1 tahun)
220.87%
Negara
NL
Perdagangan UniQure N.V. (QURE)

Kategori

Healthcare
Pendapatan untuk UniQure N.V. (QURE)
Pendapatan pada 2026 TTM: 0
Menurut laporan kewangan terkini UniQure N.V., pendapatan semasa syarikat ialah 0. Pada tahun 2026, syarikat memperoleh pendapatan sebanyak 0, sama dengan pendapatan pada tahun 2026 yang berjumlah 0. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi UniQure N.V. dari 2026 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
Tidak cukup data untuk tarikh yang disediakan.
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH